InnoCare Pharma Limited provided earnings guidance for the year ended December 31, 2021. For the period, the group expects to record a consolidated net loss of not more than approximately RMB 100 million as compared with a consolidated net loss of approximately RMB 464 million for the same period in 2020.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.35 HKD | +0.69% | -3.97% | -36.87% |
31/05 | InnoCare Pharma CEO Boosts Shareholding to 7.16% | MT |
31/05 | InnoCare Pharma Grants Over 1.7 Million Shares Under Incentive Scheme | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.87% | 1.1B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- 9969 Stock
- News InnoCare Pharma Limited
- InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended December 31, 2021